Literature DB >> 34570066

Sociodemographic and Biomedical Correlates of Developmental Delay in 2- and 4-Year-Olds with Sickle Cell Disease.

Jeffrey Schatz1, Laura Reinman, Sarah E Bills, Julia D Johnston.   

Abstract

BACKGROUND: Developmental delay occurs frequently in sickle cell disease (SCD). Psychosocial and biomedical factors contribute to delays, but most studies have not examined the timing of risk factors and developmental delay. We examined sociodemographic and biomedical factors to evaluate whether risks of developmental delay differed across 2 developmental periods.
METHODS: We examined Ages and Stages Questionnaire, second edition (ASQ-2), outcomes in 2-year-olds (n = 100) and 4-year-olds (n = 101) with SCD. ASQ-2 data were obtained from routine developmental screenings administered as part of health care between 2009 and 2016 at a single hematology clinic. Medical record reviews were used to identify sociodemographic and biomedical factors associated with positive screenings for developmental delay.
RESULTS: Two-year-olds with positive ASQ-2 screenings (n = 32; 32%) were less likely to have private health insurance or to have been in formal daycare and more likely to have a severe SCD genotype. Four-year-olds with positive screenings (n = 40; 40%) were more likely to have a severe SCD genotype or an abnormal transcranial Doppler ultrasound (TCD) examination indicating high stroke risk. The strength of the association between positive screenings and insurance status, severe genotypes, and TCD examinations differed across the 2 age groups. Domain-level outcomes on the ASQ-2 also differed across the 2 age groups.
CONCLUSION: The cross-sectional data indicate biomedical and psychosocial risks are related to developmental delay, but the association with specific risk factors differs across age.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34570066      PMCID: PMC8942869          DOI: 10.1097/DBP.0000000000001011

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.988


  25 in total

Review 1.  Fetal hemoglobin in sickle cell anemia.

Authors:  Idowu Akinsheye; Abdulrahman Alsultan; Nadia Solovieff; Duyen Ngo; Clinton T Baldwin; Paola Sebastiani; David H K Chui; Martin H Steinberg
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

2.  Neurocognitive development of young children with sickle cell disease through three years of age.

Authors:  Robert J Thompson; Kathryn E Gustafson; Melanie J Bonner; Russell E Ware
Journal:  J Pediatr Psychol       Date:  2002 Apr-May

3.  Standards and indications for cardiopulmonary sleep studies in children. American Thoracic Society.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1996-02       Impact factor: 21.405

4.  Neurodevelopmental deficits among infants and toddlers with sickle cell disease.

Authors:  Penny Glass; Tara Brennan; Jichuan Wang; Lori Luchtman-Jones; Lewis Hsu; Christen M Bass; Sohail Rana; Brenda Martin; Caroline Reed; Yao Iris Cheng; Victor Gordeuk
Journal:  J Dev Behav Pediatr       Date:  2013 Jul-Aug       Impact factor: 2.225

5.  Developmental Screening in Pediatric Sickle Cell Disease: Disease-Related Risk and Screening Outcomes in 4 Year Olds.

Authors:  Jeffrey Schatz; Alyssa Schlenz; Laura Reinman; Kelsey Smith; Carla W Roberts
Journal:  J Dev Behav Pediatr       Date:  2017-10       Impact factor: 2.225

6.  Developmental function in toddlers with sickle cell anemia.

Authors:  F Daniel Armstrong; T David Elkin; R Clark Brown; Penny Glass; Sohail Rana; James F Casella; Ram V Kalpatthi; Steven Pavlakis; Zhibao Mi; Winfred C Wang
Journal:  Pediatrics       Date:  2013-01-06       Impact factor: 7.124

7.  Silent cerebral infarcts in very young children with sickle cell anaemia are associated with a higher risk of stroke.

Authors:  Maria I Cancio; Kathleen J Helton; Jane E Schreiber; Matthew P Smeltzer; Guolian Kang; Winfred C Wang
Journal:  Br J Haematol       Date:  2015-06-07       Impact factor: 6.998

8.  The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease.

Authors:  Eve Puffer; Jeffrey Schatz; Carla W Roberts
Journal:  Child Neuropsychol       Date:  2007-03       Impact factor: 2.500

9.  Silent infarcts in young children with sickle cell disease.

Authors:  Janet L Kwiatkowski; Robert A Zimmerman; Avrum N Pollock; Wendy Seto; Kim Smith-Whitley; Justine Shults; Anne Blackwood-Chirchir; Kwaku Ohene-Frempong
Journal:  Br J Haematol       Date:  2009-06-04       Impact factor: 6.998

10.  The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease.

Authors:  F G Moser; S T Miller; J A Bello; C H Pegelow; R A Zimmerman; W C Wang; K Ohene-Frempong; A Schwartz; E P Vichinsky; D Gallagher; T R Kinney
Journal:  AJNR Am J Neuroradiol       Date:  1996-05       Impact factor: 3.825

View more
  1 in total

1.  Neurocognitive functioning in preschool children with sickle cell disease.

Authors:  Andrew M Heitzer; Diana L Cohen; Victoria I Okhomina; Ana Trpchevska; Brian Potter; Jennifer Longoria; Jerlym S Porter; Jeremie H Estepp; Allison King; Misham Henley; Guolian Kang; Jane S Hankins
Journal:  Pediatr Blood Cancer       Date:  2021-12-31       Impact factor: 3.838

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.